Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Board of Directors of Rosneft Oil Company recommended that dividends be paid for 9 months 2023

11/15/23 ROSN

Bloomberg has learned details of Yandex's new restructuring plan

11/14/23 YNDX

US sanctions will not affect Segezha Group's operations

11/14/23 SGZH

Yandex may sell all Russian assets

11/14/23 YNDX

Aeroflot's passenger turnover grew by 30.1% in October

11/14/23 AFLT

Electrozinc shareholders approved the liquidation of the company

11/14/23 ELTZ

Shareholders of Avangard Bank approved dividends for 9 months 2023

11/14/23 AVAN

Uralsib reported for 9 months of 2023 by RAS

11/14/23 USBN

Home Depot reported for 9 months of 2023

11/14/23 HD

Sberbank for the first time provided a guarantee using a smart contract

11/14/23 SBER